These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer. Paplomata E; Nahta R Expert Opin Biol Ther; 2018 Mar; 18(3):335-341. PubMed ID: 29350568 [TBL] [Abstract][Full Text] [Related]
5. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE. Johnston SRD; Hegg R; Im SA; Park IH; Burdaeva O; Kurteva G; Press MF; Tjulandin S; Iwata H; Simon SD; Kenny S; Sarp S; Izquierdo MA; Williams LS; Gradishar WJ J Clin Oncol; 2018 Mar; 36(8):741-748. PubMed ID: 29244528 [TBL] [Abstract][Full Text] [Related]
6. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE. Johnston SRD; Hegg R; Im SA; Park IH; Burdaeva O; Kurteva G; Press MF; Tjulandin S; Iwata H; Simon SD; Kenny S; Sarp S; Izquierdo MA; Williams LS; Gradishar WJ J Clin Oncol; 2021 Jan; 39(1):79-89. PubMed ID: 32822287 [TBL] [Abstract][Full Text] [Related]
7. The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer. Blackwell K; Gligorov J; Jacobs I; Twelves C Clin Breast Cancer; 2018 Apr; 18(2):95-113. PubMed ID: 29525430 [TBL] [Abstract][Full Text] [Related]
8. Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars. Tesch ME; Gelmon KA Drugs; 2020 Nov; 80(17):1811-1830. PubMed ID: 33021725 [TBL] [Abstract][Full Text] [Related]
10. Integrating trastuzumab biosimilars and HER2-directed therapies into HER2-positive breast cancer management. Cuellar S Am J Manag Care; 2020 Mar; 26(2 Suppl):S32-S40. PubMed ID: 32282173 [TBL] [Abstract][Full Text] [Related]
11. Trastuzumab in Breast Cancer Treatment: The Era of Biosimilars. Peliçário Vargas B; Sari MHM; Ferreira LM Anticancer Agents Med Chem; 2022; 22(14):2507-2516. PubMed ID: 35236272 [TBL] [Abstract][Full Text] [Related]
12. ABP 980: A Trastuzumab Biosimilar. Dhillon S BioDrugs; 2018 Oct; 32(5):511-514. PubMed ID: 30264234 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial. von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292 [TBL] [Abstract][Full Text] [Related]
14. Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation. Yamashita-Kashima Y; Shu S; Osada M; Fujimura T; Yoshiura S; Harada N; Yoshimura Y Cancer Chemother Pharmacol; 2020 Nov; 86(5):641-654. PubMed ID: 32997196 [TBL] [Abstract][Full Text] [Related]
15. Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial. Xu B; Zhang Q; Sun T; Li W; Teng Y; Hu X; Bondarenko I; Adamchuk H; Zhang L; Trukhin D; Wang S; Zheng H; Tong Z; Shparyk Y; Wang Q; BioDrugs; 2021 May; 35(3):337-350. PubMed ID: 33826080 [TBL] [Abstract][Full Text] [Related]
16. Recognizing and addressing challenges to the adoption of trastuzumab biosimilars and HER2-targeted therapies. Whalen J Am J Manag Care; 2020 Mar; 26(2 Suppl):S23-S31. PubMed ID: 32282172 [TBL] [Abstract][Full Text] [Related]
17. Challenges in the implementation of trastuzumab biosimilars: an expert panel's recommendations. Pivot X; Aulagner G; Blay JY; Fumoleau P; Kaliski A; Sarkozy F; Limat S Anticancer Drugs; 2015 Nov; 26(10):1009-16. PubMed ID: 26352219 [TBL] [Abstract][Full Text] [Related]
18. Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab. Alexeev SM; Khorinko AV; Mukhametshina GZ; Shelepen KG; Burdaeva ON; Kulik SA; Satheesh CT; Srivastava K; Vikranth M; Kryukov F; Paltusova AN; Shustova MS; Ivanov RA BMC Cancer; 2020 Aug; 20(1):783. PubMed ID: 32819305 [TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin Chen X; Li C; Ewesuedo R; Yin D Cancer Chemother Pharmacol; 2019 Jul; 84(1):83-92. PubMed ID: 31053945 [TBL] [Abstract][Full Text] [Related]
20. The evolution of biosimilars in oncology, with a focus on trastuzumab. Nixon NA; Hannouf MB; Verma S Curr Oncol; 2018 Jun; 25(Suppl 1):S171-S179. PubMed ID: 29910660 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]